Accessibility Menu
Creo Medical Group Plc logo

Creo Medical Group Plc(LSE) CREO

Current Price£0.14
Market Cap£62.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-83%
5 Year-93%
1 Year+3%
1 Month+3%
Creo Medical Group Plc last closing stock price
MetricPriceDate
Last closeGBX 13.882026-07-22
Creo Medical Group Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.6%GBX 14.252026-07-15
1 month+2.81%GBX 13.502026-06-22
3 month+8.02%GBX 12.852026-04-23
Year to date+40.2%GBX 9.902025-12-31
1 year+2.81%GBX 13.502025-07-22
3 year-59.77%GBX 34.502023-07-21
5 year-92.53%GBX 185.842021-07-23
Since inception-82.63%GBX 0.802016-12-09

Creo Medical Group Plc Financials at a Glance

Market Cap

£62.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£36.30M

Net Income (TTM)

-£17.10M

EPS (TTM)

£0.01

P/E Ratio

10.84

Dividend

£0.00

Beta (Volatility)

0.07 (Low)

Price

£0.14

Volume

158,560

Open

£0.14

Previous Close

£0.14

Daily Range

£0.14 - £0.14

52-Week Range

£0.10 - £0.19

Estimated Earnings Date

Sep 30, 2026

CREO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Creo Medical Group Plc

Creo Medical Limited is a UK-based company specializing in the development of innovative electrosurgical medical devices for surgical endoscopy applications. Founded in 2003, the company is headquartered in Chepstow and offers a range of advanced energy platforms and instruments designed to enhance therapeutic interventions.

Products and Services
  • Croma: An advanced energy platform powering various multi-modal instruments
  • Speedboat Inject: A versatile energy instrument for flexible endoscopic procedures
  • MicroBlate Flex: A flexible microwave ablation device for targeted tissue treatment
Growth Outlook
  • Recent quarterly revenue increased to £3.8 million, showing potential for growth
  • Strong product pipeline with innovative devices targeting surgical endoscopy
  • Market demand for minimally invasive surgical solutions continues to rise
Financial Highlights
  • Trailing twelve months (TTM) revenue of £15.1 million, indicating steady performance
  • Current ratio of 3.22 suggests strong liquidity position
  • Net income margin of 0.88% reflects potential for profitability improvement
Creo Medical Limited is positioned in the healthcare sector, focusing on medical devices that cater to the growing demand for minimally invasive surgical solutions. The company's flagship product, the Croma platform, is designed to enhance the efficacy of various surgical procedures, making it a valuable asset in the medical field. The recent increase in quarterly revenue indicates a positive trend, suggesting that the company is on a path toward growth. The financial metrics reveal a solid liquidity position, with a current ratio of 3.22, which is favorable for meeting short-term obligations. The TTM revenue of £15.1 million demonstrates consistent performance, while the net income margin indicates room for improvement in profitability. As the market for advanced surgical devices expands, Creo Medical Limited is well-positioned to capitalize on emerging opportunities, making it an intriguing prospect for potential investors.
AI Generated • Jul 3, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

109

CEO

Craig Jonathan Gulliford

Website

www.creomedical.com

Headquarters

Chepstow, WA NP16 5UH, GB

CREO Financials

Key Financial Metrics (TTM)

Gross Margin

31.67%

Operating Margin

-345.00%

Net Income Margin

88.33%

Return on Equity

9.56%

Return on Capital

-38.26%

Return on Assets

8.97%

Earnings Yield

9.23%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£62.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

449.14M

Volume

158.56K

Avg. Volume

741.34K

Financials (TTM)

Gross Profit

£16.90M

Operating Income

-£46.20M

EBITDA

-£40.80M

Operating Cash Flow

-£32.60M

Capital Expenditure

-£500.00K

Free Cash Flow

-£33.10M

Cash & ST Invst.

£12.40M

Total Debt

£4.10M

Creo Medical Group Plc Performance Analysis

Creo Medical Group Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 27,169,0008.0%
20232023-12-31GBP 4,000,000-85.3%
20242024-12-31GBP 4,000,0000.0%
20252025-12-31GBP 6,000,00050.0%
Creo Medical Group Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-300.7%
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-3172.7%
Creo Medical Group Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP -0.14-0.6%
20232023-12-31GBP -0.07-51.7%
20242024-12-31GBP -0.0812.0%
20252025-12-31GBP 0.01N/A
Creo Medical Group Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-21.0%
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31-169.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

£3.80M

-75.8%

Gross Profit

£900.00K

-84.5%

Gross Margin

23.68%

N/A

Market Cap

£62.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£599.21K

N/A

Employees

104

N/A

Net Income

-£11.60M

+0.0%

EBITDA

-£10.20M

+10.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

£12.40M

-33.0%

Total Debt

£4.10M

-50.6%

Accounts Receivable

£6.90M

-12.7%

Inventory

£2.50M

-69.1%

Long Term Debt

£1.80M

-65.4%

Short Term Debt

£2.30M

-25.8%

Return on Assets

8.97%

N/A

Return on Invested Capital

-39.96%

N/A

Free Cash Flow

-£34.20M

-375.0%

Operating Cash Flow

-£34.20M

-434.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KOO.LKooth plc
£1.58+0.00%
HEMO.LHemogenyx Pharmaceuticals Plc
£7.60-0.78%
HVO.LhVIVO plc
£0.07+3.85%
NCYT.LNovacyt S.A.
£0.38+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.00+0.04%
AALAmerican Airlines Group
$14.79-0.03%
NOKNokia
$10.28-0.03%
INTCIntel
$102.62-0.03%

Questions About CREO

What is the current price of Creo Medical Group Plc?

Creo Medical Group Plc is trading at £0.14 per share.

What is the 52-week range for Creo Medical Group Plc?

Over the past 52 weeks, Creo Medical Group Plc has traded between £0.10 and £0.19.

How much debt does Creo Medical Group Plc have?

As of the most recent reporting period, Creo Medical Group Plc reported total debt of £4.10M.

How much cash does Creo Medical Group Plc have on hand?

Creo Medical Group Plc reported £12.40M in cash and cash equivalents in its most recent financial results.

What is Creo Medical Group Plc’s dividend yield?

Creo Medical Group Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services